The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC74647 in HCV-infected Subjects - Trial NCT04201275
Access comprehensive clinical trial information for NCT04201275 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sunshine Lake Pharma Co., Ltd. and is currently Completed. The study focuses on Chronic Hepatitis C. Target enrollment is 28 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sunshine Lake Pharma Co., Ltd.
Timeline & Enrollment
Phase 1
Dec 18, 2019
Jan 21, 2020
Primary Outcome
Adverse Events,laboratory abnormalities and other abnormalities,Antiviral Activity,Sequence changes in the NS5A coding region,Cmax,Tmax,AUC,t1/2
Summary
The goal of this study is to assess the tolerability, pharmacokinetics and antiviral activity
 of HEC74647 in HCV treatment naïve subjects with genotypes 1-6.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04201275
Non-Device Trial